Urban P, Pavlíková M, Sivonová M, Kaplán P, Tatarková Z, Kaminska B, Lehotský J
Department of Medical Biochemistry, Jessenius Faculty of Medicine, Comenius University, Malá Hora 4, 03601 Martin, Slovak Republic.
Cell Mol Neurobiol. 2009 Mar;29(2):181-92. doi: 10.1007/s10571-008-9309-7. Epub 2008 Sep 19.
Simvastatin is a cholesterol-lowering agent whose functional significance and neuroprotective mechanism in ischemic brain injury is not yet solved. The purpose of this study is to evaluate the effect of simvastatin on ischemic brain injury. We examined the endoplasmic reticulum stress response (UPR/unfolded protein response), by measuring the mRNA and protein levels of specific genes such as ATF6, GRP78, and XBP1 after 15 min 4-VO ischemia and different times of reperfusion (1, 3, and 24 h). The results from the group of naïve ischemic rats were compared with results from the group of pre-treated animals with simvastatin. The results of the experiments showed significant increase in all genes at the mRNA level in ischemic phase (about 43% for XBP1, 58% for GRP78, and 39% for ATF6 more than control). The protein level of XBP1 was decreased in pre-treated animals at ischemic phase and first hour of reperfusion (about 15% less), and did not reach control levels. The protein levels of GRP78 were maximal at third hour of reperfusion in statin group with a small decrease at 24 h of reperfusion in both groups. The levels of ATF6 mRNA in statin-treated animals was higher in comparison to non-statin animals at the ischemic phase and the third hour of reperfusion (about 35% higher), which was also translated into the higher protein level. This could indicate that one of the main proteins targeted to enhance neuroprotective effect to ER during the first two hours of reperfusion was ATF6 protein, the levels of which were 60% higher than in non-treated animals. These data suggest that simvastatin, in addition to the proposed neuroprotective effect, exerts a neuroprotective role in the attenuation of ER stress response after acute ischemic/reperfusion insult.
辛伐他汀是一种降胆固醇药物,其在缺血性脑损伤中的功能意义和神经保护机制尚未明确。本研究旨在评估辛伐他汀对缺血性脑损伤的影响。我们通过检测在15分钟四血管闭塞缺血及不同再灌注时间(1小时、3小时和24小时)后,特定基因如ATF6、GRP78和XBP1的mRNA和蛋白水平,来研究内质网应激反应(未折叠蛋白反应/UPR)。将单纯缺血大鼠组的结果与辛伐他汀预处理动物组的结果进行比较。实验结果显示,在缺血期所有基因的mRNA水平均显著升高(XBP1比对照组高约43%,GRP78高58%,ATF6高39%)。预处理动物在缺血期和再灌注第1小时,XBP1的蛋白水平降低(约低15%),未达到对照组水平。辛伐他汀组GRP78的蛋白水平在再灌注第3小时达到最高,两组在再灌注24小时时均略有下降。在缺血期和再灌注第3小时,辛伐他汀治疗动物的ATF6 mRNA水平高于未用他汀类药物的动物(约高35%),其蛋白水平也更高。这可能表明,在再灌注的前两小时内,增强对内质网神经保护作用的主要蛋白之一是ATF6蛋白,其水平比未治疗动物高60%。这些数据表明,辛伐他汀除了具有已提出的神经保护作用外,在急性缺血/再灌注损伤后对内质网应激反应的减轻中也发挥神经保护作用。